RE: More news!Here is the content of the NR:
PharmaGap Updates Guidance On Anticipated Timing Of Results From Testing At National Cancer Institute
OTTAWA, Aug. 6 /CNW Telbec/ - PharmaGap Inc. (TSX-V: GAP) ("PharmaGap" or"the Company") today wishes to provide updated guidance to the marketregarding the anticipated timing of receipt of test results from the NationalCancer Institute ("NCI"). This morning, the Company announced test results of its lead cancer drugGAP107B8 (formerly PhG-alpha-1) at the Ottawa Hospital Research Institute("OHRI"). The Company wishes to ensure that the market remains fully aware ofthe content and timing of its external testing program previously announced. Testing of GAP107B8 is also ongoing at the NCI in its 60 cell line humancancer tumor panel, and the Company is advised to expect test results withinthe next two weeks, which remains in accordance with expectations previouslyannounced. Full results will be released to the public following a shortperiod of analysis by Company scientists and advisors. While testing at OHRI was focused on ovarian cancer, the testing at theNCI is on a wide variety of human cancers, including breast, colorectal, lung,ovarian, kidney, prostate, leukemia and various central nervous system cancersand melanomas.